Kiora Pharmaceuticals, Inc. cash flow to debt ratio of -2.70K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kiora Pharmaceuticals, Inc.'s free cash flow has decreased 217.76% from $8.55M last year to $-10.07M, signaling decreasing performance

Kiora Pharmaceuticals, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Kiora Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.02 today, signaling weakened financials

Kiora Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Kiora Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Kiora Pharmaceuticals, Inc.'s profit margin has decreased (100.00%) in the last year from 22.47% to 0.00%, signaling decreasing performance

Kiora Pharmaceuticals, Inc.'s short-term assets of $21.75M exceed its short-term liabilities of $3.63M

Kiora Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kiora Pharmaceuticals, Inc.'s return on equity of -63.39%, is lower than 15.00%, indicating bad performance

Kiora Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kiora Pharmaceuticals, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Kiora Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Kiora Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Kiora Pharmaceuticals, Inc.'s yearly earnings has decreased 401.42% since last year from $3.59M to $-10.84M, signaling decreasing performance

Kiora Pharmaceuticals, Inc.'s yearly revenue has decreased 100.00% since last year from $16.02M to $0.00, signaling decreasing performance

ROIC -53.16% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kiora Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Kiora Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Kiora Pharmaceuticals, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Kiora Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Kiora Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kiora Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kiora Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kiora Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Kiora Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kiora Pharmaceuticals, Inc. has a price-to-book ratio of 0.95x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Kiora Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue